9NC (a topoisomerase I inhibitor) in prostate and breast cell lines [48], anti-mitotic agents ENMD-1198 and MKC-1 in prostate cancer cell lines [49], have all been shown to exert their effect through upregulation of RKIP. This evidence concerns the gene PEBP1 and prostate carcinoma.